

Pere GinÀ's

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9411031/publications.pdf>

Version: 2024-02-01

390
papers

50,789
citations

1118

115
h-index

1919

214
g-index

421
all docs

421
docs citations

421
times ranked

19452
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Renal Replacement Therapy for Acute Kidney Injury in Severe Alcohol-Associated Hepatitis as a Bridge to Transplant or Recovery. <i>Digestive Diseases and Sciences</i> , 2022, 67, 697-707. | 1.1 | 7 |
| 2 | Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228. | 3.6 | 107 |
| 3 | Ductular reaction promotes intrahepatic angiogenesis through Slit2â€Roundabout 1 signaling. <i>Hepatology</i> , 2022, 75, 353-368. | 3.6 | 20 |
| 4 | Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 107-114. | 1.8 | 21 |
| 5 | Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 148-155. | 6.1 | 98 |
| 6 | Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6. | 2.4 | 42 |
| 7 | The EASLâ€Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116. | 6.3 | 257 |
| 8 | Improving Outcome Prediction in Alcohol-Associated Hepatitis: Blood Urea Nitrogen and Albumin Help. <i>Mayo Clinic Proceedings</i> , 2022, 97, 436-438. | 1.4 | 2 |
| 9 | Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure. <i>JHEP Reports</i> , 2022, 4, 100482. | 2.6 | 14 |
| 10 | Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. <i>PLoS ONE</i> , 2022, 17, e0265153. | 1.1 | 18 |
| 11 | Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112. | 2.0 | 5 |
| 12 | Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6. | 2.4 | 80 |
| 13 | Patterns of kidney dysfunction in acuteâ€onâ€chronic liver failure: Relationship with kidney and patientsâ€™ outcome. <i>Hepatology Communications</i> , 2022, 6, 2121-2131. | 2.0 | 8 |
| 14 | Long-term albumin treatment in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2022, 76, 1306-1317. | 1.8 | 16 |
| 15 | EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath. <i>Journal of Hepatology</i> , 2022, , . | 1.8 | 0 |
| 16 | Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021, 73, 571-585. | 3.6 | 56 |
| 17 | Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€onâ€chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 240-248. | 1.4 | 11 |
| 18 | Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. <i>Gastroenterology</i> , 2021, 160, 206-218.e13. | 0.6 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections. <i>Hepatology</i> , 2021, 74, 296-311. | 3.6 | 21 |
| 20 | PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108. | 1.8 | 149 |
| 21 | Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219. | 1.8 | 16 |
| 22 | SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158. | 3.7 | 49 |
| 23 | Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <i>Liver International</i> , 2021, 41, 1556-1564. | 1.9 | 16 |
| 24 | Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100233. | 2.6 | 14 |
| 25 | Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 441-460. | 1.0 | 2 |
| 26 | Reply. <i>Gastroenterology</i> , 2021, 160, 2206. | 0.6 | 0 |
| 27 | Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data". <i>Gut</i> , 2021, , gutjnl-2021-324926. | 6.1 | 0 |
| 28 | Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048. | 3.6 | 311 |
| 29 | Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). <i>Digestive and Liver Disease</i> , 2021, 53, 738-745. | 0.4 | 5 |
| 30 | Robert W Schrier, an influential observer from outside Hepatology (1936-2021). <i>Journal of Hepatology</i> , 2021, 74, 1281-1282. | 1.8 | 0 |
| 31 | The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673. | 3.6 | 67 |
| 32 | The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134. | 1.8 | 30 |
| 33 | A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. <i>Journal of Hepatology</i> , 2021, 75, 275-283. | 1.8 | 23 |
| 34 | Liver cirrhosis. <i>Lancet, The</i> , 2021, 398, 1359-1376. | 6.3 | 515 |
| 35 | Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. <i>Liver International</i> , 2021, 41, 2729-2732. | 1.9 | 6 |
| 36 | ...A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , . | | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Editorial: microRNAs for the diagnosis of fatty liver disease in the population“are we inching closer towards the target?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 557-558. | 1.9 | 1 |
| 38 | Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41. | 3.7 | 75 |
| 39 | Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis. <i>Journal of Hepatology</i> , 2020, 72, 581-582. | 1.8 | 5 |
| 40 | Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1040-1042. | 2.4 | 1 |
| 41 | Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701. | 1.8 | 223 |
| 42 | The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854. | 1.8 | 282 |
| 43 | Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. <i>Scientific Reports</i> , 2020, 10, 15558. | 1.6 | 30 |
| 44 | Hospital-Acquired Versus Community-Acquired Acute Kidney Injury in Patients With Cirrhosis: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1505-1512. | 0.2 | 12 |
| 45 | Hepatorenal syndrome: pathophysiology, diagnosis, and management. <i>BMJ</i> , The, 2020, 370, m2687. | 3.0 | 116 |
| 46 | Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00159. | 1.3 | 32 |
| 47 | Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis “ a US population-based study. <i>Journal of Hepatology</i> , 2020, 73, 1092-1099. | 1.8 | 43 |
| 48 | Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138. | 6.1 | 190 |
| 49 | Reply to: “Transition of AKI to CKD in cirrhosis” effect of baseline eGFR and unanswered questions. <i>Journal of Hepatology</i> , 2020, 73, 738-739. | 1.8 | 0 |
| 50 | Clinical Application of Kidney Biomarkers in Cirrhosis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 710-719. | 2.1 | 55 |
| 51 | Chronic Kidney Disease in Cirrhosis: Emerging Complication With Negative Impact in the Liver Transplant Setting. <i>Liver Transplantation</i> , 2020, 26, 483-484. | 1.3 | 2 |
| 52 | Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. <i>Hepatology</i> , 2020, 71, 1106-1116. | 3.6 | 22 |
| 53 | Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. <i>Journal of Hepatology</i> , 2020, 72, 1132-1139. | 1.8 | 43 |
| 54 | Statins: Old drugs as new therapy for liver diseases?. <i>Journal of Hepatology</i> , 2019, 70, 194-202. | 1.8 | 108 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177. | 0.3 | 18 |
| 56 | Editorial: evaluating cirrhosis progression—lessons from the heart. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 709-710. | 1.9 | 1 |
| 57 | Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151. | 1.8 | 104 |
| 58 | Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177. | 0.1 | 7 |
| 59 | Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out". <i>Journal of Hepatology</i> , 2019, 70, 812. | 1.8 | 0 |
| 60 | Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. <i>Annals of Hepatology</i> , 2019, 18, 144-154. | 0.6 | 11 |
| 61 | Hypervolemic Hyponatremia (Liver). <i>Frontiers of Hormone Research</i> , 2019, 52, 104-112. | 1.0 | 7 |
| 62 | Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1999-2003. | 1.4 | 11 |
| 63 | Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476. | 2.2 | 134 |
| 64 | Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Hepatology</i> , 2019, 70, 319-333. | 3.6 | 114 |
| 65 | Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10. | 0.6 | 296 |
| 66 | Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647. | 1.8 | 101 |
| 67 | Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. <i>Hepatology</i> , 2019, 69, 2180-2195. | 3.6 | 52 |
| 68 | Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. <i>Liver International</i> , 2019, 39, 1246-1255. | 1.9 | 64 |
| 69 | Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1. | 2.4 | 59 |
| 70 | New Strategies for the Management of Decompensated Cirrhosis: Long-Term Albumin Administration for Everyone?. <i>Hepatology</i> , 2019, 69, 2289-2291. | 3.6 | 2 |
| 71 | Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411. | 1.8 | 225 |
| 72 | Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701. | 3.6 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 914-920. | 1.4 | 16 |
| 74 | EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 406-460. | 1.8 | 1,762 |
| 75 | High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1138-1145.e5. | 2.4 | 180 |
| 76 | Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3. | 2.4 | 127 |
| 77 | More Than Meets the Eye in Using Interleukin 6 as a Marker of Inflammation and Prognostic Factor for Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 630-632. | 2.4 | 0 |
| 78 | Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502. | 2.4 | 83 |
| 79 | Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002. | 3.6 | 76 |
| 80 | Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut</i> , 2018, 67, 1870-1880. | 6.1 | 375 |
| 81 | Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379. | 1.3 | 47 |
| 82 | Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. <i>PLoS ONE</i> , 2018, 13, e0200656. | 1.1 | 21 |
| 83 | Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 23. | 18.1 | 172 |
| 84 | Hepatorenal syndrome in the era of acute kidney injury. <i>Liver International</i> , 2018, 38, 1891-1901. | 1.9 | 42 |
| 85 | Transient elastography for alcoholic liver disease: a step forward. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 589-591. | 3.7 | 6 |
| 86 | Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259. | 1.8 | 152 |
| 87 | Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. <i>Annals of Hepatology</i> , 2018, 17, 0-10. | 0.6 | 0 |
| 88 | A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. <i>Hepatology</i> , 2017, 66, 555-563. | 3.6 | 91 |
| 89 | Terlipressin for hepatorenal syndrome: ready for prime time. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 75-76. | 3.7 | 3 |
| 90 | Acute-on-chronic liver failure: an update. <i>Gut</i> , 2017, 66, 541-553. | 6.1 | 472 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. <i>Hepatology</i> , 2017, 66, 953-968. | 3.6 | 39 |
| 92 | Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 535-538. | 0.8 | 0 |
| 93 | Effects of alfa ₂ system on kidney and circulatory function in patients with cirrhosis and refractory ascites. <i>Liver Transplantation</i> , 2017, 23, 583-593. | 1.3 | 37 |
| 94 | Impact of Acute-on-Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. <i>Digestive and Liver Disease</i> , 2017, 49, e54. | 0.4 | 3 |
| 95 | Screening studies of transient elastography and FibroTest in the general population – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246-247. | 3.7 | 0 |
| 96 | Juan Rod s In Memoriam. <i>Gastroenterology</i> , 2017, 152, 1249-1250. | 0.6 | 0 |
| 97 | Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1003-1013.e3. | 2.4 | 67 |
| 98 | Reply to: "Are we still searching for the fifth element of MELD?" <i>Journal of Hepatology</i> , 2017, 66, 247-248. | 1.8 | 0 |
| 99 | Liver injury and glatiramer acetate, an uncommon association: case report and literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 367-372. | 1.5 | 9 |
| 100 | Pro: Acute-on-chronic liver failure. <i>Liver Transplantation</i> , 2017, 23, 1318-1324. | 1.3 | 3 |
| 101 | Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival. <i>Hepatology</i> , 2017, 66, 1842-1853. | 3.6 | 119 |
| 102 | Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. <i>Scientific Reports</i> , 2017, 7, 1829. | 1.6 | 30 |
| 103 | Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216. | 3.6 | 39 |
| 104 | Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. <i>Liver International</i> , 2017, 37, 385-395. | 1.9 | 39 |
| 105 | Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 438-445.e5. | 2.4 | 125 |
| 106 | Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. <i>American Journal of Medicine</i> , 2017, 130, 372-375. | 0.6 | 31 |
| 107 | Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. <i>Critical Care</i> , 2017, 21, 321. | 2.5 | 19 |
| 108 | Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. <i>PLoS ONE</i> , 2016, 11, e0157371. | 1.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Response to nosocomial spontaneous bacterial peritonitis: discussing a specific infection treatment algorithm. <i>Liver International</i> , 2016, 36, 1075-1076. | 1.9 | 0 |
| 110 | Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545. | 6.1 | 103 |
| 111 | LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. <i>Scientific Reports</i> , 2016, 6, 35610. | 1.6 | 25 |
| 112 | Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260. | 3.7 | 131 |
| 113 | Acute-on-Chronic Liver Failure: The Role of Precipitating Illness. <i>Seminars in Liver Disease</i> , 2016, 36, 117-122. | 1.8 | 22 |
| 114 | Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Terlipressin and Beyond. <i>Gastroenterology</i> , 2016, 150, 1525-1527. | 0.6 | 12 |
| 115 | Targeting the renin-angiotensin system in liver fibrosis. <i>Hepatology International</i> , 2016, 10, 730-732. | 1.9 | 4 |
| 116 | Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264. | 3.6 | 550 |
| 117 | Management of uninfected and infected ascites in cirrhosis. <i>Liver International</i> , 2016, 36, 109-115. | 1.9 | 43 |
| 118 | Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920. | 1.8 | 35 |
| 119 | Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041. | 18.1 | 320 |
| 120 | Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. <i>Scientific Reports</i> , 2016, 6, 32341. | 1.6 | 101 |
| 121 | Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. <i>Scientific Reports</i> , 2016, 6, 25487. | 1.6 | 125 |
| 122 | The TLR10 polymorphism rs4129009 is associated to poor 28-day survival in patients with cirrhosis and acute on chronic liver failure precipitated by bacterial infection. <i>Digestive and Liver Disease</i> , 2016, 48, e16. | 0.4 | 0 |
| 123 | The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic?. <i>Current Hepatology Reports</i> , 2016, 15, 53-59. | 0.4 | 0 |
| 124 | Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 57-65. | 1.8 | 112 |
| 125 | Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735. | 1.8 | 243 |
| 126 | Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582. | 1.8 | 196 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. <i>American Journal of Kidney Diseases</i> , 2016, 67, 318-328. | 2.1 | 74 |
| 128 | Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. <i>Hepatology</i> , 2016, 63, 207-216. | 3.6 | 18 |
| 129 | Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. <i>Gut</i> , 2016, 65, 840-851. | 6.1 | 14 |
| 130 | Integrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells. <i>Scientific Reports</i> , 2015, 5, 11549. | 1.6 | 79 |
| 131 | Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. <i>Liver Transplantation</i> , 2015, 21, 1347-1354. | 1.3 | 48 |
| 132 | Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. <i>Liver International</i> , 2015, 35, 2079-2081. | 1.9 | 4 |
| 133 | Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252. | 3.6 | 493 |
| 134 | Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0128145. | 1.1 | 97 |
| 135 | Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0145147. | 1.1 | 19 |
| 136 | Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772. | 3.6 | 230 |
| 137 | Preface. <i>Digestive Diseases</i> , 2015, 33, 1-1. | 0.8 | 0 |
| 138 | Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI" To be or not to be? <i>Journal of Hepatology</i> , 2015, 62, 743-744. | 1.8 | 2 |
| 139 | Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537. | 6.1 | 405 |
| 140 | Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974. | 1.8 | 571 |
| 141 | The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840. | 1.8 | 289 |
| 142 | Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 534-538. | 0.8 | 20 |
| 143 | Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S131-S143. | 1.8 | 358 |
| 144 | Hepatorenal syndrome: The last pieces of the puzzle or not yet?. <i>Hepatology</i> , 2015, 62, 352-354. | 3.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. <i>Journal of Hepatology</i> , 2015, 63, 593-600. | 1.8 | 53 |
| 146 | Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2015, 62, 493-495. | 1.8 | 1 |
| 147 | Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622. | 6.1 | 86 |
| 148 | Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. <i>Critical Care</i> , 2014, 18, 700. | 2.5 | 41 |
| 149 | Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. <i>Hepatology</i> , 2014, 59, 1505-1513. | 3.6 | 68 |
| 150 | Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281. | 1.8 | 259 |
| 151 | Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324. | 1.8 | 685 |
| 152 | Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <i>Journal of Hepatology</i> , 2014, 60, 955-961. | 1.8 | 100 |
| 153 | CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. <i>Gut</i> , 2014, 63, 1782-1792. | 6.1 | 118 |
| 154 | Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047. | 1.8 | 741 |
| 155 | From Refractory Ascites to Dilutional Hyponatremia and Hepatorenal Syndrome: Current Options for Treatment. <i>Current Hepatology Reports</i> , 2014, 13, 189-197. | 0.4 | 1 |
| 156 | The biliary epithelium gives rise to liver progenitor cells. <i>Hepatology</i> , 2014, 60, 1367-1377. | 3.6 | 158 |
| 157 | A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6. | 0.6 | 353 |
| 158 | Reply to: "To close the stable door before the horse has bolted". <i>Journal of Hepatology</i> , 2014, 60, 679-680. | 1.8 | 0 |
| 159 | Chronic kidney disease: A major concern in liver transplantation in the XXI century. <i>Journal of Hepatology</i> , 2014, 61, 196-197. | 1.8 | 7 |
| 160 | Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. <i>Journal of Hepatology</i> , 2014, 61, 35-42. | 1.8 | 98 |
| 161 | Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10. | 0.6 | 255 |
| 162 | Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013, 28, 301-305. | 1.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Hyponatremia in Cirrhosis: Evaluation and Treatment. , 2013, , 145-157. | | 1 |
| 164 | Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. Journal of Hepatology, 2013, 59, 1184-1192. | 1.8 | 102 |
| 165 | Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology, 2013, 58, 1757-1765. | 3.6 | 120 |
| 166 | A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. Journal of Hepatology, 2013, 59, 474-481. | 1.8 | 249 |
| 167 | Current treatment strategies for hepatorenal syndrome. Clinical Liver Disease, 2013, 2, 136-139. | 1.0 | 2 |
| 168 | Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut, 2013, 62, 452-460. | 6.1 | 167 |
| 169 | Reply to: "Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open" Journal of Hepatology, 2013, 58, 640. | 1.8 | 4 |
| 170 | Reply to: "Acute-on-chronic liver failure" Its definition remains unclear" Journal of Hepatology, 2013, 59, 191. | 1.8 | 2 |
| 171 | Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9. | 0.6 | 2,211 |
| 172 | LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. Journal of Hepatology, 2013, 58, 51-57. | 1.8 | 129 |
| 173 | Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology, 2013, 58, 1836-1846. | 3.6 | 327 |
| 174 | Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Current Opinion in Organ Transplantation, 2013, 18, 265-270. | 0.8 | 10 |
| 175 | Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrology Dialysis Transplantation, 2012, 27, 2625-2628. | 0.4 | 37 |
| 176 | Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116. | 6.1 | 121 |
| 177 | Management of critically-ill cirrhotic patients. Journal of Hepatology, 2012, 56, S13-S24. | 1.8 | 113 |
| 178 | Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 65-71.e3. | 2.4 | 155 |
| 179 | Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology, 2012, 56, 571-578. | 1.8 | 115 |
| 180 | Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology, 2012, 56, 1040-1046. | 1.8 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 267-273. | 1.8 | 191 |
| 182 | Reply to: "Encephalopathy or hepatic encephalopathy?" <i>Journal of Hepatology</i> , 2012, 57, 929-930. | 1.8 | 0 |
| 183 | Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. <i>Journal of Hepatology</i> , 2012, 57, 759-765. | 1.8 | 179 |
| 184 | Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. <i>Journal of Hepatology</i> , 2012, 57, 1135-1140. | 1.8 | 87 |
| 185 | Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3. | 0.6 | 355 |
| 186 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. <i>Digestive and Liver Disease</i> , 2012, 44, 239-244. | 0.4 | 17 |
| 187 | Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. <i>Journal of Hepatology</i> , 2012, 57, 1199-1206. | 1.8 | 116 |
| 188 | Acute-on chronic liver failure. <i>Journal of Hepatology</i> , 2012, 57, 1336-1348. | 1.8 | 545 |
| 189 | Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. <i>Annals of Hepatology</i> , 2012, 11, 399-403. | 0.6 | 10 |
| 190 | Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. <i>Hepatology</i> , 2012, 55, 1551-1561. | 3.6 | 498 |
| 191 | Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. <i>Hepatology</i> , 2012, 55, 1931-1941. | 3.6 | 177 |
| 192 | Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis. <i>American Journal of Kidney Diseases</i> , 2012, 59, 874-885. | 2.1 | 58 |
| 193 | Terlipressin for Hepatorenal Syndrome: Predictors of Response. <i>Frontiers of Gastrointestinal Research</i> , 2011, , 172-177. | 0.1 | 1 |
| 194 | Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. <i>Gastroenterology</i> , 2011, 140, 488-496.e4. | 0.6 | 311 |
| 195 | Management of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2011, 60, 412-421. | 6.1 | 64 |
| 196 | The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1472-1480. | 0.2 | 33 |
| 197 | Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2011, 55, 564-573. | 1.8 | 96 |
| 198 | Pharmacological management of hepatorenal syndrome: Lessons from non-responders. <i>Journal of Hepatology</i> , 2011, 55, 268-269. | 1.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Acute-on-chronic liver failure: the kidneys. <i>Current Opinion in Critical Care</i> , 2011, 17, 184-189. | 1.6 | 38 |
| 200 | Hepatorenal syndrome, pharmacological therapy, and liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 1244-1246. | 1.3 | 11 |
| 201 | Renal Dysfunction and Pathogenesis and Treatment of Ascites and Hepatorenal Syndrome in Cirrhosis. , 2011, , 102-112. | | 1 |
| 202 | Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2010, 51, 219-226. | 3.6 | 211 |
| 203 | Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. <i>Hepatology</i> , 2010, 51, NA-NA. | 3.6 | 96 |
| 204 | Chrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. <i>Hepatology</i> , 2010, 51, 974-985. | 3.6 | 141 |
| 205 | Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. <i>Hepatology</i> , 2010, 51, 1567-1576. | 3.6 | 117 |
| 206 | Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010, 52, 1783-1790. | 3.6 | 88 |
| 207 | Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. <i>Liver International</i> , 2010, 30, 31-41. | 1.9 | 44 |
| 208 | Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010, 30, 1137-1142. | 1.9 | 87 |
| 209 | Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290. | 1.8 | 78 |
| 210 | Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. <i>Journal of Hepatology</i> , 2010, 53, 1135-1145. | 1.8 | 97 |
| 211 | Diuretic agents for ascites: joining forces from the start?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 310-311. | 8.2 | 1 |
| 212 | Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G726-G734. | 1.6 | 110 |
| 213 | Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. <i>Liver Transplantation</i> , 2009, 15, 300-305. | 1.3 | 18 |
| 214 | Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S1-S34. | 1.3 | 135 |
| 215 | Is albumin infusion necessary after large volume paracentesis? Pro " main arguments. <i>Liver International</i> , 2009, 29, 636-638. | 1.9 | 23 |
| 216 | Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, e4-e7. | 0.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2009, 136, 1639-1650. | 0.6 | 197 |
| 218 | Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1382-1389. | 0.2 | 206 |
| 219 | Renal Failure in Cirrhosis. <i>New England Journal of Medicine</i> , 2009, 361, 1279-1290. | 13.9 | 713 |
| 220 | Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G147-G156. | 1.6 | 79 |
| 221 | A Patient With Cirrhosis and Increasing Creatinine Level: What Is It and What to Do?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1287-1291. | 2.4 | 3 |
| 222 | Portal hypertension. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 195-201. | 1.0 | 34 |
| 223 | What's new in the treatment of ascites and spontaneous bacterial peritonitis. <i>Current Gastroenterology Reports</i> , 2008, 10, 7-14. | 1.1 | 9 |
| 224 | Effects of sataavaptan, a selective vasopressin V ₂ receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213. | 3.6 | 183 |
| 225 | Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. <i>Hepatology</i> , 2008, 48, 1002-1010. | 3.6 | 267 |
| 226 | Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study. <i>Gastroenterology</i> , 2008, 134, 1352-1359. | 0.6 | 541 |
| 227 | Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670. | 0.9 | 504 |
| 228 | A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756. | 0.2 | 268 |
| 229 | Predicting Mortality in Cirrhosis – Serum Sodium Helps. <i>New England Journal of Medicine</i> , 2008, 359, 1060-1062. | 13.9 | 39 |
| 230 | The Management of Ascites and Hyponatremia in Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 043-058. | 1.8 | 79 |
| 231 | Pathogenesis and Treatment of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2008, 28, 081-095. | 1.8 | 171 |
| 232 | Complications of Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 001-001. | 1.8 | 2 |
| 233 | MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2007, 56, 1283-1290. | 6.1 | 180 |
| 234 | Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2007, 46, 935-946. | 1.8 | 135 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Vaptans: A promising therapy in the management of advanced cirrhosis. <i>Journal of Hepatology</i> , 2007, 46, 1150-1152. | 1.8 | 26 |
| 236 | Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. <i>Gastroenterology</i> , 2007, 132, 687-697. | 0.6 | 108 |
| 237 | Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 818-824. | 0.6 | 639 |
| 238 | Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. <i>Gastroenterology</i> , 2007, 133, 2019-2028. | 0.6 | 41 |
| 239 | Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived. <i>Hepatology</i> , 2007, 46, 1685-1687. | 3.6 | 12 |
| 240 | Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. <i>Liver Transplantation</i> , 2007, 13, 1017-1027. | 1.3 | 24 |
| 241 | Liver Transplant Using Donors After Unexpected Cardiac Death: Novel Preservation Protocol and Acceptance Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 1849-1855. | 2.6 | 279 |
| 242 | Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053. | 1.9 | 142 |
| 243 | Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2006, 10, 371-385. | 1.0 | 16 |
| 244 | Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143. | 0.6 | 179 |
| 245 | Hyponatremia in cirrhosis: clinical features and management. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 1144-1151. | 0.9 | 20 |
| 246 | Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. <i>Hepatology</i> , 2006, 44, 1288-1295. | 3.6 | 279 |
| 247 | Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542. | 3.6 | 349 |
| 248 | Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. <i>Hepatology</i> , 2006, 44, 1555-1563. | 3.6 | 49 |
| 249 | New Treatments of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2006, 26, 254-264. | 1.8 | 33 |
| 250 | Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G877-G884. | 1.6 | 54 |
| 251 | Therapy Insight: management of hepatorenal syndrome. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 338-348. | 1.7 | 22 |
| 252 | Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , 2005, 41, 579-587. | 3.6 | 79 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. <i>Hepatology</i> , 2005, 41, 1282-1289. | 3.6 | 338 |
| 254 | Circulatory function and hepatorenal syndrome in cirrhosis. <i>Hepatology</i> , 2005, 42, 439-447. | 3.6 | 537 |
| 255 | Management of Refractory Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1187-1191. | 2.4 | 32 |
| 256 | Management of complications of cirrhosis in patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, S124-S133. | 1.8 | 56 |
| 257 | Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. <i>Journal of Hepatology</i> , 2005, 43, 317-323. | 1.8 | 105 |
| 258 | Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. <i>Journal of Hepatology</i> , 2005, 43, 272-282. | 1.8 | 78 |
| 259 | Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. <i>Gastroenterology</i> , 2005, 129, 1944-1953. | 0.6 | 232 |
| 260 | Liver Fibrogenesis: A New Role for the Renin-Angiotensin System. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1346-1355. | 2.5 | 141 |
| 261 | Mechanisms of Sodium Retention, Ascites Formation, and Renal Dysfunction in Cirrhosis. , 2005, , 65-84. | | 3 |
| 262 | Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. <i>Hepatology</i> , 2004, 39, 1075-1087. | 3.6 | 62 |
| 263 | Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. <i>Hepatology</i> , 2004, 39, 1613-1622. | 3.6 | 87 |
| 264 | Management of hepatorenal syndrome: Another piece of the puzzle. <i>Hepatology</i> , 2004, 40, 16-18. | 3.6 | 19 |
| 265 | Effects of contrast media on renal function in patients with cirrhosis: A prospective study. <i>Hepatology</i> , 2004, 40, 646-651. | 3.6 | 61 |
| 266 | Contrast medium-associated renal dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2004, 40, 1474-1474. | 3.6 | 3 |
| 267 | Management of Cirrhosis and Ascites. <i>New England Journal of Medicine</i> , 2004, 350, 1646-1654. | 13.9 | 721 |
| 268 | Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. <i>Journal of Hepatology</i> , 2004, 40, 140-146. | 1.8 | 203 |
| 269 | Goodbye from Barcelona!. <i>Journal of Hepatology</i> , 2004, 41, 893-895. | 1.8 | 1 |
| 270 | Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. <i>Hepatology</i> , 2003, 38, 452-459. | 3.6 | 73 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266. | 3.6 | 744 |
| 272 | Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929. | 3.6 | 186 |
| 273 | Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. <i>Gastroenterology</i> , 2003, 125, 117-125. | 0.6 | 317 |
| 274 | Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. <i>Gastroenterology</i> , 2003, 124, 933-939. | 0.6 | 280 |
| 275 | Hepatorenal syndrome. <i>Lancet, The</i> , 2003, 362, 1819-1827. | 6.3 | 543 |
| 276 | Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929. | 3.6 | 88 |
| 277 | External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2002, 97, 2374-2378. | 0.2 | 27 |
| 278 | Increased plasma levels of neuropeptide Y in hepatorenal syndrome. <i>Journal of Hepatology</i> , 2002, 36, 349-355. | 1.8 | 23 |
| 279 | Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. <i>Gastroenterology</i> , 2002, 122, 1658-1676. | 0.6 | 143 |
| 280 | Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. <i>Gastroenterology</i> , 2002, 123, 1839-1847. | 0.6 | 523 |
| 281 | Good news for hepatorenal syndrome. <i>Hepatology</i> , 2002, 36, 504-506. | 3.6 | 18 |
| 282 | Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. <i>Hepatology</i> , 2002, 36, 941-948. | 3.6 | 497 |
| 283 | A prognostic model for predicting survival in cirrhosis with ascites. <i>Journal of Hepatology</i> , 2001, 34, 46-52. | 1.8 | 225 |
| 284 | Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. <i>Journal of Hepatology</i> , 2001, 34, 222-229. | 1.8 | 24 |
| 285 | Human myofibroblastic hepatic stellate cells express Ca ²⁺ -activated K ⁺ channels that modulate the effects of endothelin-1 and nitric oxide. <i>Journal of Hepatology</i> , 2001, 35, 739-748. | 1.8 | 27 |
| 286 | The model for end-stage liver disease (MELD) score predicts survival in patients with spontaneous bacterial peritonitis, and with ascites. <i>Gastroenterology</i> , 2001, 120, A378. | 0.6 | 4 |
| 287 | In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. <i>Hepatology</i> , 2001, 33, 956-962. | 3.6 | 57 |
| 288 | Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. <i>Hepatology</i> , 2001, 34, 671-676. | 3.6 | 273 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 289 | Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001, 7, 649-651. | 1.3 | 16 |
| 290 | Diagnosis and treatment of hepatorenal syndrome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 945-957. | 1.0 | 10 |
| 291 | Hepatorenal syndrome. <i>Liver Transplantation</i> , 2000, 6, S63-S71. | 1.3 | 31 |
| 292 | HEPATORENAL SYNDROME. <i>Clinics in Liver Disease</i> , 2000, 4, 487-507. | 1.0 | 21 |
| 293 | Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. <i>Gastroenterology</i> , 2000, 119, 794-805. | 0.6 | 69 |
| 294 | Angiotensin II induces contraction and proliferation of human hepatic stellate cells. <i>Gastroenterology</i> , 2000, 118, 1149-1156. | 0.6 | 459 |
| 295 | Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. <i>Journal of Hepatology</i> , 2000, 33, 43-48. | 1.8 | 381 |
| 296 | Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. <i>Hepatology</i> , 1999, 30, 501-509. | 3.6 | 30 |
| 297 | Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. <i>American Journal of Gastroenterology</i> , 1999, 94, 994-999. | 0.2 | 11 |
| 298 | Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. <i>New England Journal of Medicine</i> , 1999, 341, 403-409. | 13.9 | 1,519 |
| 299 | Hepatorenal Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1833-1839. | 3.0 | 58 |
| 300 | Increased renal and vascular cytosolic phospholipase A2 activity in rats with cirrhosis and ascites. <i>Hepatology</i> , 1998, 27, 42-47. | 3.6 | 17 |
| 301 | Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. <i>Hepatology</i> , 1998, 27, 35-41. | 3.6 | 296 |
| 302 | Increased cerebrovascular resistance in cirrhotic patients with ascites. <i>Hepatology</i> , 1998, 28, 39-44. | 3.6 | 138 |
| 303 | Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. <i>Hepatology</i> , 1998, 28, 416-422. | 3.6 | 374 |
| 304 | Hyponatremia in cirrhosis: From pathogenesis to treatment. <i>Hepatology</i> , 1998, 28, 851-864. | 3.6 | 237 |
| 305 | Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1998, 115, 147-156. | 0.6 | 63 |
| 306 | Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. <i>Gastroenterology</i> , 1998, 114, 336-343. | 0.6 | 103 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 307 | Contraction of human hepatic stellate cells activated in culture: A role for voltage-operated calcium channels. <i>Journal of Hepatology</i> , 1998, 29, 398-408. | 1.8 | 54 |
| 308 | Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom?. <i>Journal of Hepatology</i> , 1998, 29, 490-494. | 1.8 | 31 |
| 309 | Nitric Oxide as a Mediator of Hemodynamic Abnormalities and Sodium and Water Retention in Cirrhosis. <i>New England Journal of Medicine</i> , 1998, 339, 533-541. | 13.9 | 396 |
| 310 | Pathophysiology of Renal Dysfunction in Cirrhosis. <i>Digestion</i> , 1998, 59, 11-15. | 1.2 | 9 |
| 311 | Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 1997, 17, 233-247. | 1.8 | 83 |
| 312 | Pathogenesis of Ascites in Cirrhosis. <i>Seminars in Liver Disease</i> , 1997, 17, 175-189. | 1.8 | 104 |
| 313 | PATHOPHYSIOLOGY, COMPLICATIONS, AND TREATMENT OF ASCITES. <i>Clinics in Liver Disease</i> , 1997, 1, 129-155. | 1.0 | 21 |
| 314 | Practical Recommendations for the Treatment of Ascites and Its Complications. <i>Drugs</i> , 1997, 54, 571-580. | 4.9 | 21 |
| 315 | Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 645-653. | 1.8 | 59 |
| 316 | Urinary endothelin-like immunoreactivity in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 810-816. | 1.8 | 15 |
| 317 | Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. <i>Journal of Hepatology</i> , 1997, 26, 614-620. | 1.8 | 84 |
| 318 | Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 723-733. | 1.4 | 8 |
| 319 | 10 Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 365-385. | 0.9 | 18 |
| 320 | TIPS and refractory ascites. Lessons from the recent history of ascites therapy. <i>Journal of Hepatology</i> , 1996, 25, 221-223. | 1.8 | 21 |
| 321 | Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 506-512. | 1.8 | 35 |
| 322 | Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 1996, 25, 916-923. | 1.8 | 57 |
| 323 | Management of ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis in cirrhosis. <i>Current Opinion in Gastroenterology</i> , 1995, 11, 233-237. | 1.0 | 1 |
| 324 | Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis. <i>Hepatology</i> , 1995, 22, 124-131. | 3.6 | 62 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. <i>Hepatology</i> , 1995, 22, 479-487. | 3.6 | 41 |
| 326 | Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. <i>Hepatology</i> , 1995, 22, 1856-1862. | 3.6 | 60 |
| 327 | Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. <i>Gastroenterology</i> , 1995, 109, 1624-1630. | 0.6 | 165 |
| 328 | Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. <i>Journal of Hepatology</i> , 1995, 22, 389-398. | 1.8 | 49 |
| 329 | Treatment of patients with cirrhosis and refractory ascites using LeVein shunt with titanium tip: Comparison with therapeutic paracentesis*1. <i>Hepatology</i> , 1995, 22, 124-131. | 3.6 | 54 |
| 330 | Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: Evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis*1. <i>Hepatology</i> , 1995, 21, 1625-1631. | 3.6 | 9 |
| 331 | Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of Cirrhosis. <i>Seminars in Liver Disease</i> , 1994, 14, 14-22. | 1.8 | 94 |
| 332 | Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099. | 3.6 | 111 |
| 333 | Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591. | 3.6 | 43 |
| 334 | Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. <i>Hepatology</i> , 1994, 20, 839-844. | 3.6 | 124 |
| 335 | Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. <i>Journal of Hepatology</i> , 1994, 20, 282-288. | 1.8 | 80 |
| 336 | Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591. | 3.6 | 6 |
| 337 | Effect of Dipyridamole on Kidney Function in Cirrhosis. <i>Hepatology</i> , 1993, 17, 59-64. | 3.6 | 33 |
| 338 | Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257. | 3.6 | 215 |
| 339 | Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , 1993, 17, 788-793. | 3.6 | 136 |
| 340 | Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806. | 3.6 | 63 |
| 341 | Mechanism of sodium retention and ascites formation in cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, S24-S28. | 1.8 | 33 |
| 342 | Paracentesis in the management of cirrhotic ascites. <i>Journal of Hepatology</i> , 1993, 17, S14-S18. | 1.8 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 343 | Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , 1993, 104, 1485-1491. | 0.6 | 198 |
| 344 | Precision in nutritional diagnoses. <i>Gastroenterology</i> , 1993, 105, 1923. | 0.6 | 1 |
| 345 | Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236. | 0.6 | 820 |
| 346 | Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257. | 3.6 | 15 |
| 347 | Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. <i>Gastroenterology</i> , 1992, 102, 1077-1079. | 0.6 | 37 |
| 348 | Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1992, 102, 280-286. | 0.6 | 44 |
| 349 | Effects of somatostatin on renal function in cirrhosis. <i>Gastroenterology</i> , 1992, 103, 1868-1874. | 0.6 | 54 |
| 350 | Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1992, 102, 2114-2119. | 0.6 | 59 |
| 351 | Pharmacotherapy of Ascites Associated with Cirrhosis. <i>Drugs</i> , 1992, 43, 316-332. | 4.9 | 36 |
| 352 | Assessment of the renin-angiotensin system in cirrhotic patients. <i>Journal of Hepatology</i> , 1992, 15, 179-183. | 1.8 | 59 |
| 353 | Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. <i>Journal of Hepatology</i> , 1992, 14, 280-285. | 1.8 | 63 |
| 354 | Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. <i>Hepatology</i> , 1992, 16, 724-727. | 3.6 | 204 |
| 355 | TREATMENT OF ASCITES IN CIRRHOSIS. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 237-256. | 1.0 | 36 |
| 356 | Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. <i>Hepatology</i> , 1991, 14, 601-607. | 3.6 | 17 |
| 357 | Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. <i>New England Journal of Medicine</i> , 1991, 325, 829-835. | 13.9 | 294 |
| 358 | Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1990, 98, 146-151. | 0.6 | 208 |
| 359 | Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. <i>Gastroenterology</i> , 1990, 99, 1736-1744. | 0.6 | 179 |
| 360 | Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. <i>Hepatology</i> , 1990, 11, 379-386. | 3.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Natriuretic hormone activity in the urine of cirrhotic patients. <i>Hepatology</i> , 1990, 12, 467-475. | 3.6 | 19 |
| 362 | Norflaxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. <i>Hepatology</i> , 1990, 12, 716-724. | 3.6 | 587 |
| 363 | Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. <i>Hepatology</i> , 1990, 12, 753-760. | 3.6 | 229 |
| 364 | Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis. <i>Journal of Hepatology</i> , 1990, 11, 142-144. | 1.8 | 14 |
| 365 | Natural history of hepatocellular carcinoma in Spain. <i>Journal of Hepatology</i> , 1990, 10, 311-317. | 1.8 | 122 |
| 366 | Treatment of ascites and renal failure in cirrhosis. <i>Bailliere's Clinical Gastroenterology</i> , 1989, 3, 165-186. | 0.9 | 5 |
| 367 | Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. <i>Hepatology</i> , 1988, 8, 27-31. | 3.6 | 383 |
| 368 | Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. <i>Hepatology</i> , 1988, 8, 636-642. | 3.6 | 170 |
| 369 | Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. <i>Gastroenterology</i> , 1988, 94, 482-487. | 0.6 | 438 |
| 370 | Prostaglandin precursor fatty acids in cirrhosis with ascites: Effect of linoleic acid infusion in functional renal failure. <i>Clinical Science</i> , 1988, 74, 613-619. | 1.8 | 17 |
| 371 | Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. <i>Gastroenterology</i> , 1988, 94, 1493-1502. | 0.6 | 599 |
| 372 | Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. <i>Gastroenterology</i> , 1987, 93, 234-241. | 0.6 | 463 |
| 373 | Compensated cirrhosis: Natural history and prognostic factors. <i>Hepatology</i> , 1987, 7, 122-128. | 3.6 | 972 |
| 374 | Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: An overview with emphasis on pathogenesis. <i>American Journal of Medicine</i> , 1986, 81, 104-122. | 0.6 | 132 |
| 375 | Urinary excretion of 6-keto-prostaglandin F1 α , thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. <i>Journal of Hepatology</i> , 1986, 3, 111-117. | 1.8 | 105 |
| 376 | Sulindac Reduces the Urinary Excretion of Prostaglandins and Impairs Renal Function in Cirrhosis with Ascites. <i>Nephron</i> , 1986, 42, 298-303. | 0.9 | 66 |
| 377 | Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. <i>Hepatology</i> , 1985, 5, 457-462. | 3.6 | 299 |
| 378 | PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES. <i>Lancet</i> , The, 1985, 325, 611-612. | 6.3 | 102 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 379 | Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis. , 0, , 487-503. | | 1 |
| 380 | The Systemic Circulation in Cirrhosis. , 0, , 137-155. | | 16 |
| 381 | Medical Treatment of Ascites in Cirrhosis. , 0, , 227-240. | | 6 |
| 382 | Prognosis of Patients with Cirrhosis and Ascites. , 0, , 260-270. | | 36 |
| 383 | Liver Transplantation for Patients with Cirrhosis and Ascites. , 0, , 271-285. | | 5 |
| 384 | Hepatorenal Syndrome in Cirrhosis: Clinical Features, Diagnosis, and Management. , 0, , 341-359. | | 3 |
| 385 | The Sympathetic Nervous System in Cirrhosis. , 0, , 54-72. | | 7 |
| 386 | Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis. , 0, , 73-83. | | 2 |
| 387 | Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114. | | 1 |
| 388 | Management of ascites and spontaneous bacterial peritonitis. , 0, , 194-209. | | 0 |
| 389 | Extracellular Fluid Volume Homeostasis. , 0, , 1-14. | | 0 |
| 390 | Management of Ascites and Spontaneous Bacterial Peritonitis. , 0, , 158-167. | | 0 |